Herbs (Global Traditional) · Traditional Chinese Medicine
Akebia (Akebia quinata) (Akebia quinata)
Moderate Evidencebotanical5 PubMed Studies
Hermetica Superfood Encyclopedia
Akebia quinata is a traditional Japanese kampo herb containing triterpene saponins and quinatosides that may support glucose metabolism and inflammation control. Research indicates it enhances pancreatic beta-cell insulin secretion and reduces TNF-α-mediated inflammatory pathways.
Akebia quinata, commonly known as chocolate vine or five-leaf akebia, is a deciduous climbing shrub native to East Asia, including Japan, Korea, and China, belonging to the Lardizabalaceae family. The plant's stems, fruits, and pericarps serve as sources for medicinal extracts, typically obtained through ethanol extraction, water extraction, or isolation of specific compounds.
No human clinical trials, RCTs, or meta-analyses on Akebia quinata were identified in the available research. Current evidence is limited to preclinical in vitro and animal studies, including anti-breast cancer effects of Aq3639 compound (PMID: 39740845) and enhanced glucose-stimulated insulin secretion by stigmasterol-3-O-β-D-glucoside in pancreatic cells.
No clinically studied dosage ranges in humans have been established as human trials are absent. Preclinical studies used varying concentrations: Aq3639 at >25 μmol/L for cancer cell inhibition, 1% AQFE in skin explant models, with animal studies lacking specific dosage details. Consult a healthcare provider before starting any new supplement.
Akebia quinata (commonly used as stem/vine in TCM, known as Mu Tong or Akebia stem) contains limited conventional macronutrient data, as it is used medicinally rather than as a food source. Key bioactive compounds include: Triterpenoid saponins (akeboside series: Stb, Ste, Sth, Stg) at concentrations ranging approximately 0.5–2.8% dry weight in stem bark, with akeboside Stb being the most pharmacologically studied and linked to apoptosis induction in MCF-7 cells at IC50 13.10 μmol/L. Oleanolic acid and hederagenin serve as primary aglycone backbones of these saponins. Flavonoids including quercetin, kaempferol, and luteolin derivatives are present in measurable quantities (estimated 0.1–0.5% dry weight in aerial parts). Phenolic acids such as caffeic acid and chlorogenic acid have been identified in fruit and stem fractions. Sterols including beta-sitosterol and stigmasterol are present in the lipid fraction. The stem contains alkaloids in trace amounts. Polysaccharides are present in the fruit pulp, contributing mild fiber content (fruit pulp approximately 2–4% dietary fiber). Mineral content includes modest potassium, calcium, and magnesium, though precise concentrations are not well-characterized in standardized databases. Bioavailability of triterpenoid saponins is generally low via oral route (<5–10%) due to poor intestinal absorption; gut microbiota hydrolysis of sugar moieties may enhance aglycone absorption. The fruit pulp contains sugars (fructose and glucose, estimated 8–12% fresh weight) and small amounts of ascorbic acid. Traditional preparations use the dried stem (3–6g decoction), which concentrates saponins and flavonoids relative to fresh weight.
Akebia quinata's triterpene saponins and quinatoside compounds enhance glucose-stimulated insulin secretion from pancreatic beta-cells through improved calcium signaling. The herb's anti-inflammatory effects occur via inhibition of TNF-α-induced NF-κB pathway activation in smooth muscle cells. Additional mechanisms include modulation of glucose transporter activity and potential apoptosis induction in cancer cells through mitochondrial pathways.
Current evidence for akebia quinata comes primarily from in vitro studies using pancreatic cell lines and human smooth muscle cells. Pancreatic cell studies demonstrated significant increases in insulin secretion, while inflammatory marker studies showed reductions in TNF-α-induced cytokine production. Preliminary cancer research indicates growth inhibition in breast cancer cell lines. However, human clinical trials are lacking, and optimal dosing remains undetermined for therapeutic applications.
Safety data for akebia quinata supplementation is limited, with most research conducted in laboratory settings. Traditional use suggests general tolerability, but potential gastrointestinal upset may occur with higher doses. No specific drug interactions have been documented, though theoretical concerns exist with diabetes medications due to potential blood sugar effects. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
